Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with Simian HIV during oral pre-exposure prophylaxis

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 5, 2011, Pages 355-362

  Curtis, Kelly A ^a   Kennedy, M Susan ^a   Luckay, Amara ^a   Cong, Mian Er ^a   Youngpairoj, Ae S ^a   Zheng, Qi ^a   Smith, James ^a   Hanson, Debra ^b   Heneine, Walid ^a   Owen, S Michele ^a   García Lerma, J Gerardo ^a  

^a Division of HIV/AIDS Prevention   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

animal models; anti HIV agents; HIV antibodies; HIV infections; preexposure prophylaxis

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; PROTEIN P27; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMORAL IMMUNITY; NONHUMAN; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RHESUS MONKEY; SEROCONVERSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; DEOXYCYTIDINE; DRUG COMBINATIONS; HIV; HIV ANTIBODIES; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; MACACA MULATTA; PHOSPHONIC ACIDS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 80051549164     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182234a51     Document Type: Article

References (38)

1. Padian NS, Buvé A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372: 585-599.
2. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591-601. (Pubitemid 351650540)
3. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of motherto-child transmission of HIV infection. Cochrane Satabase Syst Rev. 2002;1:CD003510.
4. Chigwedere P, Seage GR, Lee TH, et al. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Human Retroviruses. 2008;24: 827-837. (Pubitemid 351871673)
5. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic syndr. 2005;40:96-101. (Pubitemid 41233212)
6. HPTN 052 a Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples. Available at: http://www.hptn.org/research-studies/hptn052.asp. Accessed April, 12, 2011.
7. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485-1490. (Pubitemid 27495773)
8. Garcia-Lerma JG, Paxton L, Kilmarx PH, et al. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci.;31:74-81.
9. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for highrisk US populations: current considerations in light of new findings. AIDS Patient Care STDs. 2011;25:63-71.
10. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
11. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.
12. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 2006;194:904-911. (Pubitemid 44454075)
13. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5:e28.
14. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270:1197-1199.
15. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2:14ra14.
16. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879. (Pubitemid 37070272)
17. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis North Am. 2007;21:19-48, vii. (Pubitemid 46729635)
18. Suligoi B, Galli C, Massi M, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassaybased method. J Clin Microbiol. 2002;40:4015-4020. (Pubitemid 35285783)
19. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis. 2005;40:868-873. (Pubitemid 40365508)
20. Binley JM, Trkola A, Ketas T, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis. 2000;182:945-949.
21. Selleri M, Orchi N, Zaniratti MS, et al. Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr. 2007;46:145-150. (Pubitemid 47482609)
22. Re MC, Schiavone P, Bon I, et al. Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. Int J Infect Dis. 2010 Sep 23 [Epub ahead of print].
23. Harouse JM, Gettie A, Tan RC, et al. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 1999; 284:816-819. (Pubitemid 29291349)
24. Jagodzinski LL, Wiggins DL, McManis JL, et al. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol. 2000;38:1247-1249. (Pubitemid 30140596)
25. Michael NL, Herman SA, Kwok S, et al. Development of calibrated viral load standards for groupMsubtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1MONITOR test with isolates of diverse subtypes. J Clin Microbiol. 1999;37:2557-2563. (Pubitemid 29337278)
26. Vahey M, Nau ME, Barrick S, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol. 1999;37:2533-2537. (Pubitemid 29337273)
27. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79: 10108-10125. (Pubitemid 41098552)
28. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
29. Zheng Q, Switzer W, Heneine W, et al. Reduced Viral Replication and Limited env Diversification in Macaques Failing Oral ARV PrEP. Presented at 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
30. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma antigp41 antibodies with ineffective control of initial viremia. J Virol. 2008; 82:12449-12463.
31. Killian MS, Norris PJ, Rawal BD, et al. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Human Retroviruses. 2006;22: 640-647. (Pubitemid 44061400)
32. Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol. 2007;45:415-420.
33. Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr. 2003;32:424-428. (Pubitemid 36363157)
34. Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Human Retroviruses. 2010;26:61-71.
35. Adalid-Peralta L, Godot V, Colin C, et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol. 2008;83:1060-1067. (Pubitemid 351959887)
36. Bello G, Velasco-de-Castro CA, Bongertz V, et al. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J Med Virol. 2009;81:1681-1690.
37. Kersh E, Luo W, Zheng Q, et al. Potent T Cell Immunity during Breakthrough SHIV Infection following Oral PrEP. Presented at 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
38. Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Human Retroviruses. 2010;26:61-71.